Drug intelligence / Profile preview

OZC-005

Development stage: Preclinical
Lead developer: ONCOZEN
Modality: Small Molecules

Overview

OZC-005 is a chaperone-mediated protein degradation (CMPD) agent being developed by ONCOZEN. It specifically targets the Human Epidermal Growth Factor Receptor (HER) family. Unlike traditional targeted protein degradation (TPD) approaches such as PROTACs, which utilize the ubiquitin-proteasome system, OZC-005 leverages the cell's chaperone-mediated autophagy pathway to degrade oncogenic proteins. The drug is currently in the lead optimization stage, with a primary focus on the treatment of biliary tract cancer.

Targets

ErbB (EGFR family)

Beyond the preview

Go deeper on OZC-005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OZC-005.

Explore the full profile